## **Open Access**

## Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics



Ajaz A. Bhat<sup>1†</sup>, Sabah Nisar<sup>1†</sup>, Soumi Mukherjee<sup>2†</sup>, Nirmalya Saha<sup>3†</sup>, Nageswari Yarravarapu<sup>4†</sup>, Saife N. Lone<sup>5</sup>, Tariq Masoodi<sup>6</sup>, Ravi Chauhan<sup>7</sup>, Selma Maacha<sup>8</sup>, Puneet Bagga<sup>9</sup>, Punita Dhawan<sup>10</sup>, Ammira Al-Shabeeb Akil<sup>1</sup>, Wael El-Rifai<sup>8</sup>, Shahab Uddin<sup>11,12</sup>, Ravinder Reddy<sup>13</sup>, Mayank Singh<sup>7\*</sup>, Muzafar A. Macha<sup>14\*</sup> and Mohammad Haris<sup>12,13\*</sup>

## Abstract

Gene editing has great potential in treating diseases caused by well-characterized molecular alterations. The introduction of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)–based gene-editing tools has substantially improved the precision and efficiency of gene editing. The CRISPR/Cas9 system offers several advantages over the existing gene-editing approaches, such as its ability to target practically any genomic sequence, enabling the rapid development and deployment of novel CRISPR-mediated knock-out/knock-in methods. CRISPR/Cas9 has been widely used to develop cancer models, validate essential genes as druggable targets, study drug-resistance mechanisms, explore gene non-coding areas, and develop biomarkers. CRISPR gene editing can create more-effective chimeric antigen receptor (CAR)-T cells that are durable, cost-effective, and more readily available. However, further research is needed to define the CRISPR/Cas9 system's pros and cons, establish best practices, and determine social and ethical implications. This review summarizes recent CRISPR/Cas9 developments, particularly in cancer research and immunotherapy, and the potential of CRISPR/Cas9-based screening in developing cancer precision medicine and engineering models for targeted cancer therapy, highlighting the existing challenges and future directions. Lastly, we highlight the role of artificial intelligence in refining the CRISPR system's on-target and off-target effects, a critical factor for the broader application in cancer therapeutics.

**Keywords:** CRISPR/Cas9, Artificial intelligence, Genome engineering, Cancer precision medicine, Cancer Immunotherapy, CAR T-cells, Epigenetics, Drug resistance, Cancer biomarker

<sup>†</sup>Ajaz A. Bhat and Sabah Nisar contributed equally as first co-authors

<sup>†</sup>Soumi Mukherjee, Nirmalya Saha and Nageswari Yarravarapu contributed equally as second co-authors

\*Correspondence: mayank.osu@gmail.com; muzafar.aiiims@gmail.com; Mohammad.Haris@pennmedicine.upenn.edu

<sup>7</sup> Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

<sup>13</sup> Center for Advanced Metabolic Imaging in Precision Medicine, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

<sup>14</sup> Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Jammu & Kashmir, India Full list of author information is available at the end of the article

## Introduction

As our understanding of the underlying genetic and molecular basis of malignancy has rapidly increased through massive tumor genetic profiling, modeling, and characterization, the ever-evolving list of molecular alterations in cells holds great potential for identifying actionable genomic events and treating malignancies. The emergence of gene-editing tools in the last few decades has enabled scientists to manipulate genomic sequences to understand gene function better and develop targeted treatments for inherited and acquired diseases. Although the 1970 discovery of restriction enzymes, the original genome editor, was a breakthrough enabling the



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.